- Conditions
- Non Small Cell Lung Cancer
- Interventions
- Pembrolizumab, stereotactic radiation therapy (SRT), Surgery (Non-interventional, standard of care)
- Drug · Radiation · Procedure
- Lead sponsor
- Sue Yom
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 1
- States / cities
- San Francisco, California
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 97–120
of 542
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- Nivolumab
- Drug
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2030
- U.S. locations
- 7
- States / cities
- West Haven, Connecticut • Washington D.C., District of Columbia • Indianapolis, Indiana + 4 more
- Conditions
- Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC), Pancreatic Ductal Adenocarcinoma
- Interventions
- Stereotactic Body Radiation (SBRT), Nivolumab, CCR2/CCR5 dual antagonist, GVAX
- Radiation · Drug
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2025
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Mycosis Fungoides, Sézary Syndrome
- Interventions
- TSEB Therapy, Brentuximab vedotin
- Radiation · Drug
- Lead sponsor
- Virginia Commonwealth University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 1
- States / cities
- Richmond, Virginia
- Conditions
- Esophageal Cancer, Gastric Cancer
- Interventions
- cisplatin, epirubicin hydrochloride, fluorouracil, oxaliplatin, adjuvant therapy, neoadjuvant therapy
- Drug · Procedure
- Lead sponsor
- Case Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 61 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2015
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Brain Metastases, Small Cell Lung Cancer
- Interventions
- NovoTTF-200A, Stereotactic Radiosurgery (SRS)
- Device · Radiation
- Lead sponsor
- Drexell Hunter Boggs
- Other
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Cancer, Lung, Metastasis
- Interventions
- Personalized Ultra-fractionated stereotactic ablative radiotherapy (PULSAR)
- Radiation
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Soft Tissue Sarcoma
- Interventions
- External Beam Radiotherapy
- Radiation
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2029
- U.S. locations
- 1
- States / cities
- Palo Alto, California
- Conditions
- Oropharynx Cancer
- Interventions
- therapeutic conventional surgery, laboratory biomarker analysis, quality-of-life assessment, intensity-modulated radiation therapy, Cisplatin, Carboplatin
- Procedure · Other · Radiation + 1 more
- Lead sponsor
- Heath Skinner
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2030
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Metastatic Prostate Cancer
- Interventions
- Atezolizumab, Abiraterone, Prednisone, GnRH analog, Stereotactic Body Radiotherapy (SBRT), Enzalutamide, Follow up
- Drug · Radiation · Other
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 8
- States / cities
- Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
- Conditions
- Head and Neck Neoplasms
- Interventions
- Pembrolizumab, Placebo, Cisplatin, Accelerated Fractionation (AFX) Radiotherapy, Standard Fractionation (SFX) Radiotherapy
- Biological · Drug · Radiation
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 804 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2024
- U.S. locations
- 24
- States / cities
- Los Angeles, California • San Francisco, California • Santa Rosa, California + 21 more
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- BIO 300 Oral Suspension, Paclitaxel, Carboplatin, Radiotherapy
- Drug · Radiation
- Lead sponsor
- Humanetics Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2020
- U.S. locations
- 4
- States / cities
- Baltimore, Maryland • Detroit, Michigan • Milwaukee, Wisconsin
- Conditions
- Refractory Non-Hodgkin Lymphoma, Relapsed Non-Hodgkin Lymphoma
- Interventions
- SIRPant-M, External-beam radiotherapy (XRT)
- Biological · Radiation
- Lead sponsor
- SIRPant Immunotherapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 3
- States / cities
- Duarte, California • Hackensack, New Jersey • Houston, Texas
- Conditions
- Lung Cancer, Esophageal Cancer
- Interventions
- Carboplatin, Paclitaxel, Radiation Therapy
- Drug · Radiation
- Lead sponsor
- Fox Chase Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- HPV-Related Squamous Cell Carcinoma, HNSCC
- Interventions
- nab-paclitaxel, Carboplatin, Nivolumab, Cisplatin, Hydroxyurea, 5-FU, Dexamethasone, Famotidine, Diphenhydramine, Paclitaxel, Transoral robotic surgery (TORS), Adjuvant RT, Chemoradiotherapy
- Drug · Procedure · Radiation
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 72 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2024
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Extensive-stage Small-cell Lung Cancer
- Interventions
- Durvalumab 50 MG/1 ML Intravenous Solution, Etoposide Injection, Cisplatin, Carboplatin, Stereotactic Body Radiotherapy
- Drug · Device
- Lead sponsor
- University of Maryland, Baltimore
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2027 – 2028
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Leukemia Lymphoblastic, Acute, Acute Myeloid Leukemia, Neoplasm Recurrent
- Interventions
- Clofarabine, Total Body Irradiation, Stem Cell Transplantation, Cyclosporine, Mycophenolate Mofetil
- Drug · Radiation · Other
- Lead sponsor
- Therapeutic Advances in Childhood Leukemia Consortium
- Other
- Eligibility
- 1 Year to 21 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2014
- U.S. locations
- 6
- States / cities
- Los Angeles, California • Columbus, Ohio • Portland, Oregon + 3 more
- Conditions
- Prostate Cancer
- Interventions
- > 15% risk of + LN
- Radiation
- Lead sponsor
- University of Florida
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 77 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2022
- U.S. locations
- 1
- States / cities
- Jacksonville, Florida
- Conditions
- Gastro-esophageal Junction (GEJ) Cancer, Esophagus Cancer
- Interventions
- PULSAR- Personalized Ultra-fractionated Stereotactic Ablative Radiotherapy, FLOT (Fluorouracil+Leucovorin+Oxaliplatin+Docetaxel)(D)
- Radiation · Drug
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Limited Stage Small Cell Lung Cancer
- Interventions
- Ociperlimab, Tislelizumab, Concurrent Chemoradiotherapy
- Drug
- Lead sponsor
- BeiGene
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 126 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Knoxville, Tennessee
- Conditions
- Pancreatic Neoplasms
- Interventions
- Ascorbate, Gemcitabine, Radiation therapy
- Drug · Radiation
- Lead sponsor
- Joseph J. Cullen
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2025
- U.S. locations
- 1
- States / cities
- Iowa City, Iowa
- Conditions
- Anal Cancer
- Interventions
- Radiation (reduced elective nodal dose (30.6 Gy), Capecitabine, Mitomycin c
- Radiation · Drug
- Lead sponsor
- University of Cincinnati
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2029
- U.S. locations
- 3
- States / cities
- Cincinnati, Ohio • Columbus, Ohio • Burlington, Vermont
- Conditions
- Chordoma
- Interventions
- Nilotinib, Radiation therapy
- Drug · Radiation
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2025
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Glioblastoma, Glioblastoma Multiforme, Gliosarcoma
- Interventions
- enzastaurin, temozolomide, radiation therapy
- Drug · Radiation
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 72 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2009
- U.S. locations
- 1
- States / cities
- San Francisco, California